Characteristics of 226 patients with high-risk AML or RAEB-t by assigned treatment
| . | . | AraC-DNR (N = 107) . | AraC-DNR + CsA (N = 119) . | ||
|---|---|---|---|---|---|
| No. . | Percent . | No. . | Percent . | ||
| Age | Median | 53 y | 54 y | ||
| Disease status | First relapse | 61 | 57 | 71 | 60 |
| Second or later relapse | 7 | 7 | 6 | 5 | |
| Refractory | 17 | 16 | 15 | 13 | |
| Secondary | 22 | 21 | 27 | 23 | |
| AML/RAEB-t | |||||
| Sex | Female | 52 | 49 | 53 | 45 |
| Male | 55 | 51 | 66 | 55 | |
| Performance status | 0-1 | 93 | 87 | 108 | 91 |
| 2 | 14 | 13 | 11 | 9 | |
| WBC (1000/μL) | Median | 4.3 | 5.4 | ||
| Range | 0.3-178 | 0.5-211 | |||
| FAB (local) | M1 | 20 | 19 | 21 | 18 |
| M2 | 26 | 24 | 36 | 30 | |
| M3 | 5 | 5 | 5 | 4 | |
| M4 | 28 | 26 | 26 | 22 | |
| M5 | 5 | 5 | 11 | 9 | |
| M6 | 3 | 3 | 4 | 3 | |
| M7 | 0 | 0 | 1 | 1 | |
| M0 | 7 | 7 | 3 | 3 | |
| AML, NOS | 9 | 8 | 5 | 4 | |
| RAEB-t | 4 | 4 | 7 | 6 | |
| Cytogenetic pattern | Favorable | 8 | 9 | 11 | 11 |
| Intermediate | 28 | 33 | 38 | 39 | |
| Unfavorable | 42 | 49 | 36 | 37 | |
| Not classified | 8 | 9 | 13 | 13 | |
| Not evaluable | 21 | — | 21 | — | |
| Pgp expression (MRK16) | Negative (D < 0.20) | 59 | 66 | 70 | 65 |
| Positive (D ≥ 0.20) | 31 | 34 | 37 | 35 | |
| Unknown | 17 | — | 12 | — | |
| . | . | AraC-DNR (N = 107) . | AraC-DNR + CsA (N = 119) . | ||
|---|---|---|---|---|---|
| No. . | Percent . | No. . | Percent . | ||
| Age | Median | 53 y | 54 y | ||
| Disease status | First relapse | 61 | 57 | 71 | 60 |
| Second or later relapse | 7 | 7 | 6 | 5 | |
| Refractory | 17 | 16 | 15 | 13 | |
| Secondary | 22 | 21 | 27 | 23 | |
| AML/RAEB-t | |||||
| Sex | Female | 52 | 49 | 53 | 45 |
| Male | 55 | 51 | 66 | 55 | |
| Performance status | 0-1 | 93 | 87 | 108 | 91 |
| 2 | 14 | 13 | 11 | 9 | |
| WBC (1000/μL) | Median | 4.3 | 5.4 | ||
| Range | 0.3-178 | 0.5-211 | |||
| FAB (local) | M1 | 20 | 19 | 21 | 18 |
| M2 | 26 | 24 | 36 | 30 | |
| M3 | 5 | 5 | 5 | 4 | |
| M4 | 28 | 26 | 26 | 22 | |
| M5 | 5 | 5 | 11 | 9 | |
| M6 | 3 | 3 | 4 | 3 | |
| M7 | 0 | 0 | 1 | 1 | |
| M0 | 7 | 7 | 3 | 3 | |
| AML, NOS | 9 | 8 | 5 | 4 | |
| RAEB-t | 4 | 4 | 7 | 6 | |
| Cytogenetic pattern | Favorable | 8 | 9 | 11 | 11 |
| Intermediate | 28 | 33 | 38 | 39 | |
| Unfavorable | 42 | 49 | 36 | 37 | |
| Not classified | 8 | 9 | 13 | 13 | |
| Not evaluable | 21 | — | 21 | — | |
| Pgp expression (MRK16) | Negative (D < 0.20) | 59 | 66 | 70 | 65 |
| Positive (D ≥ 0.20) | 31 | 34 | 37 | 35 | |
| Unknown | 17 | — | 12 | — | |
WBC indicates white blood cell; NOS, not otherwise specified.